Alexander Gozman

1.0k total citations
22 papers, 778 citations indexed

About

Alexander Gozman is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Alexander Gozman has authored 22 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Alexander Gozman's work include PARP inhibition in cancer therapy (7 papers), Heat shock proteins research (7 papers) and Genetic factors in colorectal cancer (6 papers). Alexander Gozman is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), Heat shock proteins research (7 papers) and Genetic factors in colorectal cancer (6 papers). Alexander Gozman collaborates with scholars based in United States, Italy and Israel. Alexander Gozman's co-authors include Gabriela Chiosis, Tony Taldone, Ronnie Maharaj, Anna Rodina, Cristina C. Clement, Ari Melnick, Eloisi Caldas-Lopes, Elisa de Stanchina, Ana I. Robles and Lyuba Varticovski and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Alexander Gozman

20 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexander Gozman United States	8	612	139	120	119	103	22	778
Maria Vilenchik United States	11	723 1.2×	125 0.9×	133 1.1×	95 0.8×	86 0.8×	20	931
Komal Jhaveri United States	10	639 1.0×	102 0.7×	140 1.2×	130 1.1×	80 0.8×	17	790
Wen‐Cherng Lee United States	15	627 1.0×	140 1.0×	224 1.9×	175 1.5×	62 0.6×	21	1000
Weiwen Ying United States	16	658 1.1×	59 0.4×	113 0.9×	162 1.4×	95 0.9×	27	973
Suman Chatterjee United States	7	563 0.9×	45 0.3×	164 1.4×	89 0.7×	119 1.2×	9	724
Noriaki Tatsuta United States	12	426 0.7×	40 0.3×	125 1.0×	103 0.9×	52 0.5×	21	731
Stefan O. Ochiana United States	11	471 0.8×	105 0.8×	49 0.4×	72 0.6×	78 0.8×	14	590
Yeong Sang Kim United States	13	614 1.0×	57 0.4×	179 1.5×	134 1.1×	78 0.8×	17	863
S.E. Greasley United States	19	726 1.2×	115 0.8×	153 1.3×	115 1.0×	75 0.7×	25	935
K. Boxall United Kingdom	8	444 0.7×	89 0.6×	168 1.4×	30 0.3×	87 0.8×	11	542

Countries citing papers authored by Alexander Gozman

Since Specialization

Citations

This map shows the geographic impact of Alexander Gozman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Gozman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Gozman more than expected).

Fields of papers citing papers by Alexander Gozman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Gozman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Gozman. The network helps show where Alexander Gozman may publish in the future.

Co-authorship network of co-authors of Alexander Gozman

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Gozman. A scholar is included among the top collaborators of Alexander Gozman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Gozman. Alexander Gozman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marabelle, Aurélien, David M. O’Malley, Andrew Hendifar, et al.. (2025). Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer. 6(2). 253–258. 2 indexed citations

O’Malley, David M., Giovanni M. Bariani, Philippe A. Cassier, et al.. (2025). Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results. Gynecologic Oncology. 193. 130–135. 1 indexed citations

Yap, Timothy A., Ronnie Shapira‐Frommer, Iwona Ługowska, et al.. (2025). Abstract CT004: KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers. Cancer Research. 85(8_Supplement_2). CT004–CT004. 2 indexed citations

Cai, Chen, Elisha J. Dettman, Wei Zhou, et al.. (2024). Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study. Future Oncology. 20(31). 2357–2370.

Amonkar, Mayur M., Lauren A. Abderhalden, Andrew M. Frederickson, et al.. (2024). Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis. Future Oncology. 20(13). 863–876. 2 indexed citations

Shao, Changxia, Heng Zhou, Elisha J. Dettman, et al.. (2023). Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors. JCO Precision Oncology. 7(7). e2300195–e2300195. 1 indexed citations

Wu, Xuan, Yilei Mao, Nong Xu, et al.. (2023). 601P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158. Annals of Oncology. 34. S1707–S1707. 1 indexed citations

Mao, Yimin, Xiaohua Wu, Nong Xu, et al.. (2023). 136P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158. Annals of Oncology. 34. S235–S235.

Maio, Michele, P.A. Ascierto, Nicolas Penel, et al.. (2022). 113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial. Annals of Oncology. 33. S589–S590. 3 indexed citations

10.

Cassier, Philippe A., Jean‐Pierre Delord, Matteo Simonelli, et al.. (2022). CTIM-03. PEMBROLIZUMAB MONOTHERAPY FOR MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) RECURRENT GLIOMAS: RESULTS FROM THE MULTICOHORT PHASE 2 KEYNOTE-158 STUDY. Neuro-Oncology. 24(Supplement_7). vii59–vii60. 2 indexed citations

11.

Maio, Michele, Ronnie Shapira‐Frommer, Timothy A. Yap, et al.. (2021). Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study. Cancer Research. 81(13_Supplement). CT178–CT178. 13 indexed citations

12.

Yap, Timothy A., Andrew Hendifar, Michele Maio, et al.. (2020). A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007.. Journal of Clinical Oncology. 38(15_suppl). TPS3156–TPS3156. 3 indexed citations

13.

Yap, Timothy A., Mallika Dhawan, Andrew Hendifar, et al.. (2020). Abstract CT269: A phase 2 study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007. Cancer Research. 80(16_Supplement). CT269–CT269. 1 indexed citations

14.

Zong, Hongliang, Alexander Gozman, Eloisi Caldas-Lopes, et al.. (2015). A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports. 13(10). 2159–2173. 46 indexed citations

15.

Kang, Yanlong, Tony Taldone, Hardik J. Patel, et al.. (2014). Heat Shock Protein 70 Inhibitors. 1. 2,5′-Thiodipyrimidine and 5-(Phenylthio)pyrimidine Acrylamides as Irreversible Binders to an Allosteric Site on Heat Shock Protein 70. Journal of Medicinal Chemistry. 57(4). 1188–1207. 44 indexed citations

16.

Taldone, Tony, Yanlong Kang, Hardik J. Patel, et al.. (2014). Heat Shock Protein 70 Inhibitors. 2. 2,5′-Thiodipyrimidines, 5-(Phenylthio)pyrimidines, 2-(Pyridin-3-ylthio)pyrimidines, and 3-(Phenylthio)pyridines as Reversible Binders to an Allosteric Site on Heat Shock Protein 70. Journal of Medicinal Chemistry. 57(4). 1208–1224. 37 indexed citations

17.

Rodina, Anna, Pallav D. Patel, Yanlong Kang, et al.. (2013). Identification of an Allosteric Pocket on Human Hsp70 Reveals a Mode of Inhibition of This Therapeutically Important Protein. Chemistry & Biology. 20(12). 1469–1480. 80 indexed citations

18.

Wrona, Iwona, Alexander Gozman, Tony Taldone, Gabriela Chiosis, & James S. Panek. (2010). Synthesis of Reblastatin, Autolytimycin, and Non-Benzoquinone Analogues: Potent Inhibitors of Heat Shock Protein 90. The Journal of Organic Chemistry. 75(9). 2820–2835. 51 indexed citations

19.

Caldas-Lopes, Eloisi, Leandro Cerchietti, James H. Ahn, et al.. (2009). Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences. 106(20). 8368–8373. 248 indexed citations

20.

Taldone, Tony, Alexander Gozman, Ronnie Maharaj, & Gabriela Chiosis. (2008). Targeting Hsp90: small-molecule inhibitors and their clinical development. Current Opinion in Pharmacology. 8(4). 370–374. 238 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact